Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Pevonedistat (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 17 Sep 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 17 Sep 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 29 Jan 2018 Status changed from not yet recruiting to recruiting.